AI Article Synopsis

  • Sudden deafness and vestibular loss are mostly idiopathic (90%), can be easily overlooked, but cause significant sensory impairment.
  • In 65% of cases, individuals may experience relevant or complete recovery within two weeks.
  • Treatment focuses on symptoms, commonly using steroids and heparin, but other options like dextran 40 and carbogen may also be effective, emphasizing the need for therapy even in severe situations.

Article Abstract

Clinical aspects of sudden deafness and sudden vestibular loss. The cases of sudden deafness and/or sudden vestibular loss are 90% idiopathic. Initially they can be overlooked but they can be responsible for an important sensorial impairment. In 65% of cases, and within the first two weeks, there may be a relevant or complete recovery or functional compensation. Etiology and pathogenesis are considered to be pluri-factorial; multiple virus infection including the Herpesvirus family, is the most relevant and better documented cause. Such an infection is responsible for a derangement of inner ear microcirculation, ions imbalance at labyrinthine fluids level, reduction of receptors and nervous supply function. Therapy is essentially symptomatic and therefore the most widely used drugs are cortisonics and heparin. In the Author's opinion also dextran 40, by slow endovenous drip, and carbogen (O2 95% + CO2 5%), by inhalations, are very effective with only rare contraindications. The occurrence of an important number of spontaneous improvements or even recoveries does not authorize therapeutic abstension especially in severe or delayed cases.

Download full-text PDF

Source

Publication Analysis

Top Keywords

sudden deafness
12
aspects sudden
8
sudden vestibular
8
vestibular loss
8
sudden
5
[clinical aspects
4
deafness vestibulopathy]
4
vestibulopathy] clinical
4
clinical aspects
4
deafness sudden
4

Similar Publications

Background: Sudden sensorineural hearing loss (SSNHL) is associated with abnormal changes in the brain's central nervous system. Previous studies on the brain networks of SSNHL have primarily focused on functional connectivity within the brain. However, in addition to functional connectivity, structural connectivity also plays a crucial role in brain networks.

View Article and Find Full Text PDF

Hyperbaric oxygen therapy and corticosteroids as combined treatment for acute acoustic trauma.

Eur Arch Otorhinolaryngol

January 2025

Motion Sickness and Human Performance Laboratory, The Israel Naval Medical Institute, IDF Medical Corps, Haifa, Israel.

Purpose: Acute acoustic trauma (AAT) is a sudden sensorineural hearing loss (SNHL) due to exposure to high intensity impulse noise. There are no acceptable treatment guidelines, although several studies showed steroids could be effective in restoring hearing levels. A recent report suggested that steroids combined with hyperbaric oxygen therapy (HBOT) are a superior regiment for AAT.

View Article and Find Full Text PDF

Purpose: Sudden sensorineural hearing loss (SSHL) is an abrupt hearing loss, often of unknown cause. Apheresis is a treatment option aimed at improving blood hemorheology by removing pathogenic blood components. There are currently no previous meta-analyses on its efficacy.

View Article and Find Full Text PDF

Efficacy analysis of intratympanic injection of dexamethasone at different concentrations for the treatment of unilateral idiopathic sudden sensorineural hearing loss.

Am J Otolaryngol

January 2025

Department of Otolaryngology-Head and Neck Surgery, Affiliated Hospital of Yangzhou University, No. 368 Hanjiang Middle Road, Yangzhou, Jiangsu Province 225001, PR China. Electronic address:

Objective: Our study tried to evaluate and compare the therapeutic efficacy of intratympanic injection of dexamethasone (DEX) at different concentrations for the treatment of idiopathic sudden sensorineural hearing loss (ISSNHL).

Methods: A prospective randomized controlled study was conducted on 203 patients with unilateral ISSNHL. Patients were divided into four groups: the control group (n = 47, systemic treatment only), the high-concentration group (n = 51, intratympanic injection of DEX 20 mg/ml), the medium-concentration group (n = 55, 10 mg/ml), and the low-concentration group (n = 50, 5 mg/ml).

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!